| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/06/2023 | — | Exane BNP Paribas | Downgrades | Neutral → Underperform | |
| 10/17/2023 | 8.56% | Wells Fargo | $33 → $34 | Maintains | Equal-Weight |
| 10/11/2023 | — | Exane BNP Paribas | Initiates Coverage On | → Neutral | |
| 10/10/2023 | 14.94% | B of A Securities | → $36 | Upgrades | Neutral → Buy |
| 10/03/2023 | 8.56% | Wedbush | → $34 | Initiates Coverage On | → Neutral |
| 09/27/2023 | 8.56% | Truist Securities | $33 → $34 | Maintains | Hold |
| 09/20/2023 | 14.94% | Raymond James | $33 → $36 | Maintains | Outperform |
| 09/12/2023 | 5.36% | RBC Capital | → $33 | Initiates Coverage On | → Sector Perform |
| 09/08/2023 | 11.75% | Mizuho | $31 → $35 | Upgrades | Neutral → Buy |
| 08/07/2023 | 5.36% | Wells Fargo | $32 → $33 | Maintains | Equal-Weight |
| 07/27/2023 | 11.75% | Berenberg | → $35 | Reinstates | → Buy |
| 07/27/2023 | 10.15% | BMO Capital | → $34.5 | Initiates Coverage On | → Market Perform |
| 07/26/2023 | 2.17% | Wells Fargo | → $32 | Downgrades | Overweight → Equal-Weight |
| 06/21/2023 | 5.36% | Truist Securities | $29 → $33 | Maintains | Hold |
| 05/30/2023 | -1.02% | Mizuho | $32 → $31 | Maintains | Neutral |
| 05/11/2023 | 2.17% | Wells Fargo | $30 → $32 | Maintains | Overweight |
| 05/03/2023 | 5.36% | Stifel | $36 → $33 | Maintains | Buy |
| 04/20/2023 | -4.21% | Wells Fargo | → $30 | Initiates Coverage On | → Overweight |
| 04/19/2023 | — | Wells Fargo | Initiates Coverage On | → Overweight | |
| 03/31/2023 | -20.18% | Credit Suisse | → $25 | Reiterates | → Underperform |
| 02/22/2023 | -10.6% | Citigroup | $30 → $28 | Maintains | Neutral |
| 02/15/2023 | 5.36% | Raymond James | $35 → $33 | Maintains | Outperform |
| 01/17/2023 | -1.02% | Barclays | $33 → $31 | Maintains | Equal-Weight |
| 01/09/2023 | -20.18% | Credit Suisse | → $25 | Downgrades | Neutral → Underperform |
| 11/14/2022 | 5.36% | B of A Securities | → $33 | Downgrades | Buy → Neutral |
| 11/09/2022 | 11.75% | Raymond James | $34 → $35 | Maintains | Outperform |
| 10/10/2022 | — | Baird | Downgrades | Outperform → Neutral | |
| 09/13/2022 | 8.56% | Truist Securities | $30 → $34 | Maintains | Hold |
| 08/05/2022 | 11.75% | B of A Securities | $27 → $35 | Upgrades | Underperform → Buy |
| 08/03/2022 | 8.56% | Raymond James | $33 → $34 | Maintains | Outperform |
| 06/30/2022 | -10.6% | Jefferies | $32 → $28 | Downgrades | Buy → Hold |
| 06/14/2022 | -4.21% | Truist Securities | $33 → $30 | Maintains | Hold |
| 04/26/2022 | -7.41% | Barclays | → $29 | Initiates Coverage On | → Equal-Weight |
| 03/18/2022 | 5.36% | Raymond James | $35 → $33 | Maintains | Outperform |
| 02/08/2022 | -10.6% | Credit Suisse | $31 → $28 | Maintains | Neutral |
| 02/04/2022 | 11.75% | Raymond James | $36 → $35 | Maintains | Outperform |
| 02/01/2022 | -1.02% | Credit Suisse | → $31 | Initiates Coverage On | → Neutral |
| 01/10/2022 | 14.94% | Raymond James | $38 → $36 | Maintains | Outperform |
| 10/27/2021 | -4.21% | B of A Securities | $33 → $30 | Downgrades | Neutral → Underperform |
| 10/08/2021 | 14.94% | Baird | → $36 | Initiates Coverage On | → Outperform |
| 09/23/2021 | 21.33% | Raymond James | $40 → $38 | Maintains | Outperform |
| 09/13/2021 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 08/26/2021 | 5.36% | B of A Securities | $37 → $33 | Downgrades | Buy → Neutral |
| 07/23/2021 | 37.29% | Wells Fargo | $39 → $43 | Maintains | Overweight |
| 07/14/2021 | 24.52% | Mizuho | → $39 | Assumes | → Neutral |
| 06/17/2021 | 24.52% | Scotiabank | → $39 | Downgrades | Outperform → Sector Perform |
| 06/15/2021 | 37.29% | Wolfe Research | → $43 | Initiates Coverage On | → Peer Perform |
| 01/13/2021 | 14.94% | Mizuho | → $36 | Downgrades | Buy → Neutral |
| 01/13/2021 | 27.71% | Jefferies | $35 → $40 | Upgrades | Hold → Buy |
| 12/03/2020 | 37.29% | JMP Securities | → $43 | Upgrades | Market Perform → Market Outperform |
| 11/30/2020 | 27.71% | B of A Securities | $32 → $40 | Upgrades | Underperform → Buy |
| 09/02/2020 | 11.75% | Stifel | → $35 | Reinstates | → Buy |
| 08/03/2020 | 8.56% | Raymond James | → $34 | Downgrades | Strong Buy → Outperform |
| 06/17/2020 | 5.36% | Wells Fargo | $28 → $33 | Maintains | Equal-Weight |
| 06/08/2020 | — | JMP Securities | Reinstates | → Market Perform | |
| 05/15/2020 | 8.56% | Raymond James | $32 → $34 | Upgrades | Outperform → Strong Buy |
| 04/29/2020 | 2.17% | Raymond James | $30 → $32 | Maintains | Outperform |
| 04/24/2020 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 04/23/2020 | 2.17% | SunTrust Robinson Humphrey | $36 → $32 | Maintains | Hold |
| 04/07/2020 | -20.18% | Citigroup | $44 → $25 | Maintains | Neutral |
| 03/26/2020 | -10.6% | Wells Fargo | $43 → $28 | Maintains | Equal-Weight |
| 03/25/2020 | -4.21% | Raymond James | → $30 | Upgrades | Market Perform → Outperform |
| 01/22/2020 | 40.49% | Citigroup | → $44 | Initiates Coverage On | → Neutral |
| 10/21/2019 | — | Raymond James | Downgrades | Strong Buy → Market Perform | |
| 10/14/2019 | 42.08% | B of A Securities | → $44.5 | Reinstates | → Buy |
| 09/12/2019 | 50.06% | Berenberg | → $47 | Initiates Coverage On | → Buy |
| 09/12/2019 | 40.49% | Raymond James | $42 → $44 | Maintains | Strong Buy |
| 08/23/2019 | 27.71% | Wells Fargo | $36 → $40 | Maintains | Market Perform |
| 08/08/2019 | 34.1% | Raymond James | $40 → $42 | Upgrades | Outperform → Strong Buy |
| 02/07/2019 | — | Scotiabank | Initiates Coverage On | → Sector Perform | |
| 02/07/2019 | 24.52% | Stifel | → $39 | Downgrades | Buy → Hold |
| 11/29/2018 | 24.52% | Stifel | $34 → $39 | Upgrades | Hold → Buy |
| 11/16/2018 | — | Raymond James | Upgrades | Market Perform → Outperform | |
| 11/16/2018 | — | B of A Securities | Upgrades | Underperform → Neutral |
What is the target price for Omega Healthcare Invts (OHI)?
The latest price target for Omega Healthcare Invts (NYSE: OHI) was reported by Exane BNP Paribas on November 6, 2023. The analyst firm set a price target for $0.00 expecting OHI to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Omega Healthcare Invts (OHI)?
The latest analyst rating for Omega Healthcare Invts (NYSE: OHI) was provided by Exane BNP Paribas, and Omega Healthcare Invts downgraded their underperform rating.
When is the next analyst rating going to be posted or updated for Omega Healthcare Invts (OHI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Omega Healthcare Invts, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Omega Healthcare Invts was filed on November 6, 2023 so you should expect the next rating to be made available sometime around November 6, 2024.
Is the Analyst Rating Omega Healthcare Invts (OHI) correct?
While ratings are subjective and will change, the latest Omega Healthcare Invts (OHI) rating was a downgraded with a price target of $0.00 to $0.00. The current price Omega Healthcare Invts (OHI) is trading at is $31.32, which is out of the analyst's predicted range.